Yesterday, May 4, 2016, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,916.49 to $4,828,179.42. Highlighted Stocks Traded by Insiders: PTC (PTC) - FREE Research Report Heppelmann James E, who is President and CEO at PTC, sold 25,000 shares at $36.53 on May 4, 2016. Following this transaction, the President and CEO owned 603,181 shares meaning that the stake was reduced by 3.98% with the 25,000-share transaction. Gremley Robert C, who is EVP, Technology Platform Group at PTC, sold 3,978 shares at $36.53 on May 4, 2016. Following this transaction, the EVP, Technology Platform Group owned 3,976 shares meaning that the stake was reduced by 50.01% with the 3,978-share transaction. The shares most recently traded at $35.40, down $1.13, or 3.19% since the insider transaction. Historical insider transactions for PTC go as follows:

  • 4-Week # shares sold: 17,908
  • 12-Week # shares sold: 17,908
  • 24-Week # shares sold: 52,908

The average volume for PTC has been 609,000 shares per day over the past 30 days. PTC has a market cap of $4.2 billion and is part of the technology sector and computer software & services industry. Shares are up 3.18% year-to-date as of the close of trading on Wednesday. PTC Inc. develops and delivers software products and solutions worldwide. It operates in two segments, Software Products and Services. Currently, there are 7 analysts who rate PTC a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PTC - FREE

TheStreet Quant Ratings

rates PTC as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

PTC Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Evercore Partners (EVR) - FREE Research Report

Pensa Paul, who is Contr., Principal Acct.Officer at Evercore Partners, sold 1,672 shares at $50.85 on May 4, 2016. Following this transaction, the Contr., Principal Acct.Officer owned 6,442 shares meaning that the stake was reduced by 20.61% with the 1,672-share transaction. The shares most recently traded at $49.80, down $1.05, or 2.11% since the insider transaction. Historical insider transactions for Evercore Partners go as follows:

  • 4-Week # shares sold: 19,576
  • 12-Week # shares sold: 19,576
  • 24-Week # shares sold: 19,576

The average volume for Evercore Partners has been 368,200 shares per day over the past 30 days. Evercore Partners has a market cap of $2.0 billion and is part of the financial sector and financial services industry. Shares are down 7.34% year-to-date as of the close of trading on Wednesday. Evercore Partners Inc. operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The stock currently has a dividend yield of 2.48%. The company has a P/E ratio of 50.1. Currently, there is 1 analyst who rates Evercore Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EVR - FREE

TheStreet Quant Ratings

rates Evercore Partners as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, growth in earnings per share and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Evercore Partners Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GenMark Diagnostics (GNMK) - FREE Research Report

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 331 shares at $5.79 on May 4, 2016. Following this transaction, the SVP, Human Resources owned 194,396 shares meaning that the stake was reduced by 0.17% with the 331-share transaction. Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 396 shares at $5.79 on May 4, 2016. Following this transaction, the SVP, North American Com. Ops. owned 254,202 shares meaning that the stake was reduced by 0.16% with the 396-share transaction. Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 396 shares at $5.79 on May 4, 2016. Following this transaction, the SVP, International owned 138,495 shares meaning that the stake was reduced by 0.29% with the 396-share transaction. Stier Eric, who is SVP & General Counsel at GenMark Diagnostics, sold 363 shares at $5.79 on May 4, 2016. Following this transaction, the SVP & General Counsel owned 111,560 shares meaning that the stake was reduced by 0.32% with the 363-share transaction. The shares most recently traded at $5.57, down $0.22, or 3.95% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 2,995
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 11,707
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 47,496

The average volume for GenMark Diagnostics has been 188,400 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $243.7 million and is part of the health care sector and health services industry. Shares are down 27.45% year-to-date as of the close of trading on Wednesday. GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, commercializes, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, feeble growth in its earnings per share and generally disappointing historical performance in the stock itself. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.